1. UNAIDS. 2021 Global HIV Statistics. Fact Sheet—June, 2021. [cited 2022 March 11]. https://www.unaids.org/en/resources/fact-sheet.
2. HIV.gov. U. S. Statistics. [cited 2022 March 11]. https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics.
3. Board NL, Moskovljevic M, Wu F, Siliciano RF, Siliciano JD. Engaging innate immunity in HIV-1 cure strategies. Nat Rev Immunol. 2022;22(8):499–512.
4. Segal-Maurer S, DeJesus E, Stellbrink H-J, Castagna A, Richmond GJ, Sinclair GI, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med. 2022;386(19):1793–803.
5. Daar ES, McDonald C, Crofoot G, Ruane P, Sinclair G, Patel H, et al. Safety and antiviral activity over 10 days following a single dose of subcutaneous GS-6207, a first-in-class, long-acting HIV capsid inhibitor in people living with HIV. IAS; Abstract LBPEB13; 2019.